Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$485000.0.

  • Atara Biotherapeutics' Change in Accured Expenses rose 8300.63% to -$485000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year decrease of 27104.24%. This contributed to the annual value of -$12.5 million for FY2024, which is 21301.52% down from last year.
  • Latest data reveals that Atara Biotherapeutics reported Change in Accured Expenses of -$485000.0 as of Q3 2025, which was up 8300.63% from -$7.5 million recorded in Q2 2025.
  • Atara Biotherapeutics' Change in Accured Expenses' 5-year high stood at $14.3 million during Q4 2023, with a 5-year trough of -$8.8 million in Q1 2022.
  • Over the past 4 years, Atara Biotherapeutics' median Change in Accured Expenses value was -$485000.0 (recorded in 2025), while the average stood at -$896866.7.
  • Per our database at Business Quant, Atara Biotherapeutics' Change in Accured Expenses skyrocketed by 2636851.85% in 2023 and then tumbled by 32303.37% in 2025.
  • Atara Biotherapeutics' Change in Accured Expenses (Quarter) stood at $54000.0 in 2022, then soared by 26368.52% to $14.3 million in 2023, then tumbled by 114.4% to -$2.1 million in 2024, then soared by 76.43% to -$485000.0 in 2025.
  • Its last three reported values are -$485000.0 in Q3 2025, -$7.5 million for Q2 2025, and $3.5 million during Q1 2025.